时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
To address these challenges, both the Royal College of Physicians in the United Kingdom and the Bone Health and Osteoporosis Foundation (BHOF) – formerly the National Osteoporosis Foundation (NOF) in the United States published guidelines for osteoporosis prevention and treatment in 1999 (, ).；The first osteoporosis guideline in mainland China was developed by the Chinese Society of Osteoporosis and Bone Mineral Research in 2006, however, since then, multiple guidelines have been issued by various medical specialty societies across the country ().
方法
Exclusion criteria were as follows: guidelines focusing on people with secondary osteoporosis; guidelines on osteoporotic fractures that did not mention or involve osteoporosis management; previous versions of guidelines if updated versions were available; and management protocols specific to local hospitals, organisations, communities, or rehabilitation centres.；Titles and abstracts were initially screened by two independent reviewers (TW and LX), followed by full-text screening by the same reviewers.；Reference lists of included guidelines were also manually checked to locate guidelines that met the inclusion criteria but were not captured in the database search.
核心结论
The rehabilitation guidelines provide recommendations on the types of assessments that people with osteoporosis should be subject to, including evaluations of pain levels, functional ability in daily living, quality of life, psychological function, and the risk of falls and fractures; they also cover non-pharmacological treatment options, strategies to prevent falls and fractures, and emphasise a multidimensional approach to rehabilitation including physical and psychological health, as well as patients’ awareness and understanding of osteoporosis.；Osteoporosis or fracture risk assessment tools, such as the International Osteoporosis Foundation (IOF) One-Minute Osteoporosis Check Test (), the Osteoporosis Self-Assessment Tool for Asians (OSTA) (), and the Fracture Risk Assessment Tool (FRAX) (), as well as the quantitative ultrasound (QUS) test, were suggested as screening tools to identify high-risk populations for further investigation. ‖ 结论：Furthermore, this review highlights the need for high-quality studies tailored to the Chinese context, incorporating robust economic evaluations to identify cost-effective osteoporosis management strategies.
局限
These limitations may be partly addressed through opportunistic QCT, whereby CT scans obtained for other clinical indications are used for osteoporosis assessment.；These frequencies should be interpreted in the context of guideline publication year, as recommendations for newer agents became more common over time: denosumab was recommended in all guidelines published from 2022 onwards, while romosozumab was first recommended in 2021 () and became more commonly recommended from 2023 onwards.；Both the US NOF and the UK NOGG guidelines strongly recommend incorporating non-pharmacological treatments, such as physical exercise, calcium and vitamin D supplementation, dietary modification, smoking
对本项目的价值
★☆☆☆☆ 衰弱/肌少症是少有的已有监管认可终点的老年综合征，是临床转化的最短路径。设计 systematic review；最大样本量约 8,100。
全文来源
PMC JATS 全文（正文 28,224 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Clinical guidelines for the management of osteoporosis in China: a systematic review.
- 期刊与标识：Front Endocrinol (Lausanne) · PMID 42959116 · DOI 10.3389/fendo.2026.1943964
C 级证据分级：C 级（预印本 / 观点评论，非原始研究）
本文属观点/评论类文献，不是原始研究。其论点依赖于作者对既有证据的梳理与判断，不构成新的实验证据。本站标注 C 级即为此意——阅读时请把它当作「领域内的思考框架」，而非「研究发现」。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。